Cargando…
Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life–threatening continuum of neuromuscular and cardiac toxicity
Autores principales: | Rota, Eugenia, Varese, Paola, Agosti, Sergio, Celli, Lorenzo, Ghiglione, Elisabetta, Pappalardo, Irene, Zaccone, Gabriele, Paglia, Alba, Morelli, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262799/ https://www.ncbi.nlm.nih.gov/pubmed/30533536 http://dx.doi.org/10.1016/j.ensci.2018.11.023 |
Ejemplares similares
-
Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021) -
Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
por: Cham, Jason, et al.
Publicado: (2021) -
Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor
por: Ünlütürk, Zeynep, et al.
Publicado: (2023) -
Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
por: Virgen, Cesar A, et al.
Publicado: (2023) -
Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis
por: Kufukihara, Kenji, et al.
Publicado: (2019)